Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge

Kimberly M. Clark a,1, John B. Johnson a, Nancy D. Kock b, Steven B. Mizel a, Griffith D. Parks a,⁎

a Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1064, USA
b Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1064, USA

A R T I C L E   I N F O

Article history:
Received 12 May 2011
Returned to author for revision 8 August 2011
Accepted 11 August 2011
Available online 31 August 2011

Keywords:
Parainfluenza virus
Viral vectors

A B S T R A C T

To test the potential for parainfluenza virus 5 (PIV5)-based vectors to provide protection from vaccinia virus (VACV) infection, PIV5 was engineered to express secreted VACV L1R and B5R proteins, two important antigens for neutralization of intracellular mature (IMV) and extracellular enveloped (EEV) virions, respectively. Protection of mice from lethal intranasal VACV challenge required intranasal immunization with PIV5-L1R/B5R in a prime-boost protocol, and correlated with low VACV-induced pathology in the respiratory tract and anti-VACV neutralizing antibody. Mice immunized with PIV5-L1R/B5R showed some disease symptoms following VACV challenge such as loss of weight and hunching, but these symptoms were delayed and less severe than with unimmunized control mice. While immunization with PIV5 expressing B5R alone conferred at least some protection, the most effective immunization included the PIV5 vector expressing L1R alone or in combination with PIV5-B5R. PIV5-L1R/B5R vectors elicited protection from VACV challenge even when CD8+ cells were depleted, but not in the case of mice that were defective in B cell production. Mice were protected from VACV challenge out to at least 1.5 years after immunization with PIV5-L1R/B5R vectors, and showed significant levels of anti-VACV neutralizing antibodies. These results demonstrate the potential for PIV5-based vectors to provide long lasting protection against complex human respiratory pathogens such as VACV, but also highlight the need to understand mechanisms for the generation of strong immune responses against poorly immunogenic viral proteins.

© 2011 Elsevier Inc. All rights reserved.

Introduction

The respiratory tract can be a major entry site for many pathogenic viruses, including influenza virus, paramyxoviruses, coronaviruses, pox viruses and herpes viruses. The outcomes of these viral infections can be significantly influenced by immune responses at the mucosal surfaces of the respiratory tract, including the recruitment of innate immune cells, and the activation of T cells and antibody responses (Murphy, 1994; Virgin, 2007; Woodland and Randall, 2004). As such, there is intense interest in developing vaccination strategies and viral vectors that promote strong and long lasting protective immune responses against viral respiratory tract pathogens. This is particularly important for viral infections in different anatomical regions of the respiratory tract, since the mechanisms controlling immunity in these airway compartments can differ significantly (Woodland and Randall, 2004). The overall goal of the work described here was to determine the capacity of viral vectors based on parainfluenza virus 5 (PIV5) to elicit protection against lethal respiratory tract infection by vaccinia virus (VACV).

Poxviruses such variola virus, the causative agent of smallpox, highly fatal monkey poxvirus, and VACV can establish lethal infections through the respiratory tract (e.g., Buller and Palumbo, 1991; Kaufman et al., 2008). While a live attenuated form of VACV is currently used in the United States as a licensed smallpox vaccine, a number of concerns have been raised due to risk of adverse effects of this vaccine (e.g., Jacobs et al., 2009). VACV also presents major challenges to the development of alternative vaccination approaches that are based on purified VACV proteins and heterologous vectors expressing VACV antigens (Moss, 2006). First, VACV exists in two major infectious forms: the extracellular enveloped virion (EEV) and the intracellular mature virion (IMV). Importantly, the VACV antigens that are critical for neutralization of these two forms differ (Fogg et al., 2004; Hooper et al., 2000). For example, L1R is a myristoylated transmembrane protein in the IMV form and is an important target for IMV neutralization (Aldaz-Carroll et al., 2005b; Franke et al., 1990; Wolfe et al., 1995). B5R is a membrane-anchored VACV protein with an extracellular domain containing regions that are related to some complement regulatory proteins (Engelstad et al., 1992). Antibodies against B5R are important for neutralization of the EEV form (Aldaz-Carroll et al., 2005a; Bell et al., 2004; Galmiche et al., 1999). Because antibodies that neutralize the IMV do not neutralize the
human pathogens such as variola virus, but also raise the critical issue of based vectors to provide protection against complex and highly lethal infection of B cells. These results highlight the potential for PIV5-based vectors to express soluble forms of the VACV antigens L1R and B5R. In mice from lethal I.N. VACV challenge, which was dependent on B cells expressing model antigens can elicit strong and long lasting T cell immunity in the respiratory tract against VACV infection, we engineered vectors as vaccines against complex human pathogens which infect the respiratory tract. Vaccination with purified VACV proteins or with DNA vaccines encoding VACV proteins requires multiple immunizations for protective responses (e.g., Berhanu et al., 2008; Fogg et al., 2004; Hooper et al., 2000, 2003). Finally, the VACV antigens that are important for control of infections initiated through the respiratory tract versus systemic routes (intravenous or intraperitoneal) can differ, and the immune mechanisms for protection from these different routes of infection are not completely understood (Belyakov et al., 2005; Kaufman et al., 2008).

Given the importance of developing safe and potent vaccination approaches against respiratory tract pathogens, we have developed the parainfluenza virus PIV5 as a vaccine vector (Arimilli et al., 2008; Capraro et al., 2008; Parks and Alexander-Miller, 2002). Our previous work in both mouse and ferret model systems has shown that intranasal (I.N.) delivery of PIV5 induces a potent antibody response, and that PIV5 is cleared from respiratory tissues by 7–9 days pi without evidence of systemic infection (Capraro et al., 2008). Likewise, PIV5 vectors expressing model antigens can elicit strong and long lasting T cell responses which can display a high avidity phenotype (Gray et al., 2003; Parks and Alexander-Miller, 2002). Importantly, vaccination of both ferrets and mice with recombinant PIV5 vectors did not result in overt pathology and there was no evidence of disease symptoms (Capraro et al., 2008). These desirable properties raise the potential use of PIV5 vectors as vaccines against complex human pathogens which infect the respiratory tract.

To test the hypothesis that PIV5-based vectors can elicit protective immunity in the respiratory tract against VACV infection, we engineered PIV5 vectors to express soluble forms of the VACV antigens L1R and B5R. These PIV5-L1R/B5R vectors elicited long term (>1.5 years) protection in mice from lethal I.N. VACV challenge, which was dependent on B cells but not on CD8+ cells. These results highlight the potential for PIV5-based vectors to provide protection against complex and highly lethal human pathogens such as variola virus, but also raise the critical issue of how to generate strong immunity in airway compartments against poorly immunogenic proteins such as those found with VACV.

**Results**

**Construction of PIV5 vectors expressing VACV proteins L1R and B5R**

The open reading frames for VACV L1R and B5R proteins were modified by PCR to lack sequences coding for their transmembrane domains and to encode a C-terminal HA tag for detection. These modified L1R and B5R genes were individually inserted at the HN-L junction encoded in the PIV5 infectious cDNA clone such that they were flanked by PIV5 transcription signals (Fig. 1A). Viruses were recovered from cDNA clones and were designated PIV5-L1R and PIV5-B5R. Growth analyses of PIV5-L1R and PIV5-B5R did not show detectable differences in tissue culture cells compared to WT PIV5 and expression of L1R and B5R was stable during multiple passages (not shown).

As shown in Fig. 1B, western blot analysis of lysates from cells infected with the PIV5-L1R and PIV5-B5R viruses showed HA-tagged L1R and B5R expression consistent with predicted sizes of ~21 and ~35 kDa, respectively (Aldaz-Carroll et al., 2005a, 2005b). Similar to previous data with VSV-based vectors (Braxton et al., 2010), B5R was expressed at a somewhat higher level than L1R. Examination of extracellular media (Fig. 1B, right panel) showed very efficient time-dependent release of B5R. By contrast, most of L1R was retained within the cell similar to that seen in the case of the control cytoplasmic protein thymidine kinase (TK) expressed from a PIV5 vector (Parks et al., 2002). Longer exposures showed a low level of extracellular L1R protein, consistent with secretion of this protein when linked to a signal peptide (Shinoda et al., 2009).

**Mice are protected from lethal VACV challenge after immunization with PIV5 vectors expressing L1R and B5R**

To determine if the PIV5 vectors conferred protection from lethal VACV challenge, groups of 5 mice were immunized I.N. with PBS as a control or by the I.N. or I.M. route with 10^6 PFU of both PIV5-L1R and PIV5-B5R. On day 28, mice were given a booster immunization with PBS.

![Fig. 1.](image-url) Expression of L1R and B5R from recombinant PIV5 vectors. A) Schematic diagram of PIV5 viruses used in this study. The genome structure of PIV5 is shown schematically as negative sense RNA with the insertion site for L1R and B5R genes between HN and L. Black bar denotes HA tag added to the L1R and B5R open reading frames. Le, leader; tr, trailer. B) Protein expression. A549 cells were infected at an MOI of 25 with PIV5 vectors expressing TK, L1R or B5R. At the indicated time pi, media and cell lysates were analyzed by western blotting for HA-tagged proteins or for NP. 5X denotes the L1R portion of the gel exposed 5 times longer.
L.N. or with the same dose of PIV5-L1R/BSR by either the L.N. or I.M. routes. As a positive control, mice received a single sublethal L.N. dose of VACV (10^2 PFU). Twenty one days after the boost, mice were challenged with VACV equivalent to 20 MTD_{50} by I.N. administration, and lethality and weight were monitored daily.

As shown in Fig. 2A, positive control mice that received a sublethal dose of VACV were protected from death following VACV challenge (VACV control group). By contrast, mice that received PBS or only one priming dose of the PIV5-L1R and -BSR vectors (PBS and single I.N. and I.M. groups, Fig. 2A) succumbed to infection on day 7 or 8. Most importantly, mice that received an L.N. prime followed by I.N. boost with the PIV5 vectors (I.N.–I.N., group) all survived lethal VACV infection.

Although mice immunized with PIV5-L1R/BSR did not succumb to lethal VACV challenge, they did showed signs of VACV-induced disease. This is evident in Fig. 2B which shows changes in body weight as a percentage of initial weight before challenge. Control mice immunized with a sublethal dose of VACV did not show changes in overall weight (VACV control). By contrast, animals in all other groups showed a substantial loss of weight that became evident at day 4 and maximal at day 7 or 8 post VACV challenge. Mice receiving PBS, the single dose of PIV5 vectors (I.N. and I.M. animals) or prime-boost by the I.M. route (I.M.–I.M. group) all lost substantial weight and either died or were removed from the study when loss of weight reached more than 30% of initial value. Importantly, mice given an I.N. prime and I.N. boost with the PIV5-BSR and PIV5-L1R vectors (Fig. 2B, I.N.–I.N., open triangles) also lost weight, but weight loss was delayed compared to the PBS control and these I.N.–I.N. animals began to recover weight by about day 8 post challenge.

To determine the ability of the individual PIV5 vectors to confer protection, groups of mice were given prime-boost L.N. immunizations with 10^6 PFU of PIV5-L1R alone, PIV5-BSR alone or a combination of the two vectors. Mice were challenged with 20 MTD_{50} of VACV by I.N. administration and lethality and weight were monitored daily. As shown in Fig. 2C, VACV-immunized control mice (closed triangles) survived VACV challenge, while all PBS-treated mice (open triangles) succumbed to challenge by day 7 or 8. Approximately 70–80% of mice given a combination of L1R plus B5R vectors or given the L1R vector alone showed a high level of protection from death, while mice given the B5R vector alone showed a slightly lower level of protection (~40%) from lethal VACV challenge. These results on survival from challenge were supported by the results on weight loss shown in Fig. 2D, where mice given either PIV5-L1R only or a combination of PIV5-L1R plus PIV5-BSR lost the least amount of weight following lethal VACV challenge. These results indicate that while immunization with vectors expressing B5R alone conferred at least some protection, the most effective immunization included the PIV5 vector expressing L1R alone or in combination with B5R.

To determine the degree of pathology following VACV challenge, mice were immunized L.N. with PBS as a negative control, a sublethal VACV dose as a positive control, or with 10^6 PFU of both PIV5-L1R and

![Fig. 2.](image-url)

Fig. 2. Mice vaccinated with PIV5-L1R and PIV5-BSR are protected from lethal VACV challenge. Panels A and B) Groups of 5 mice each were immunized with PBS as a control or a combination of 10^6 PFU of PIV5-L1R plus PIV5-BSR through either the L.N. or I.M. route. On day 28, PIV5-vaccinated mice were boosted with either PBS as a control (L.N. or I.M. only) or with the same dose of PIV5 vectors by the L.N. or I.M. route (L.N.–L.N. or I.M.–I.M. groups). Control groups received either a sublethal level of VACV L.N. (closed diamond, VACV control) or prime-boost with PBS (open squares). Twenty one days after the boost, mice were challenged with VACV equivalent to 20 MTD_{50} by L.N. administration. Mice were monitored daily to determine survival (panel A) and weight loss (panel B) as a percent of initial body weight. Mice were euthanized at an experimental end point when they had a loss of 30% of initial weight or development of severe disease characteristics that were indicative of terminal stages of disease. For panel A, p < 0.003 for comparison of L.N.–L.N. to I.N. only and also for L.N.–L.N. compared to L.M.–L.M. For panel B, * denotes p < 0.001 for comparison of L.N.–L.N. to VACV control. Panels C and D) Groups of 7 mice each were administered prime and boost L.N. doses of PBS (open triangle), a sublethal dose of VACV (VACV control, closed triangle), or 10^6 PFU of PIV5-L1R and PIV5-BSR alone (open square and closed circle) or in combination (closed square) on the same days described for panels A and B. Mice were then challenged with VACV and then monitored daily as in panel A. For panel C, p < 0.02 for comparison of VACV, L1 + B5, L1, and B5 groups compared to PBS control. For panel D, **; p < 0.005; *; p < 0.5 when comparing weight loss between animals immunized with PIV5-BSR alone to PIV5-L1R alone or PIV5-L1R plus PIV5-BSR, respectively.
PIV5-B5R in a prime-boost protocol as described for Fig. 2. On day 28 post boost, mice were challenged with VACV equivalent to 20 MTD50 by i.N. administration. Nasal tissue and the olfactory lobes of the brain were analyzed on day 7 post challenge by staining with hematoxylin and eosin. Control mice immunized with a sublethal dose of VACV showed intact nasal epithelium and clear nasal cavity (Fig. 3, panels A and B). By contrast, PBS-treated mice showed inflammatory exudate (panel C) filling much of the nasal cavity with a bilateral extension through the cribiform plate into the adjacent olfactory lobes (white arrows, panel C). There was extensive destruction of the nasal epithelium (black arrows, panel D), with inflammatory cells being present in submucosa and in the nasal cavity. For mice immunized with the PIV5 vectors, VACV challenge resulted in small amounts of exudates seen in the nasal cavity but there was no extension into the brain region (Fig. 3, panel E). Higher magnification showed only very low levels of inflammatory cells in the exudates and only minimal disruption of the nasal epithelium (panel F). PIV5 immunized animals showed no significant lesions in lung tissue or other organs including heart, liver, kidney and spleen (not shown). Together, these data indicate that mice immunized with PIV5-L1R and -B5R vectors show relatively low levels of pathology in the nasal tissue at day 7 post VACV challenge compared to control animals that succumb to VACV infection.

Recovery of weight loss in PIV5-L1R and -B5R immunized mice correlates with clearance of challenge VACV from the lung tissue

To determine VACV load in lung tissue following challenge infection, groups of 5 mice were immunized as described in the legend to Fig. 2 and then challenged 20 MTD50 of VACV i.N. at 21 day after the boost. On days 4, 8 and 12 post challenge, the titer of VACV in lung tissues was determined by plaque assay. As shown in Fig. 4, no VACV was detected in tissues from control mice given the sublethal dose of VACV, and this was consistent with the lack of disease symptoms in these animals. PBS-treated mice had high VACV titers in the lung tissue until day 8 when they succumbed to infection (# in Fig. 4 denotes no animals survived). Importantly, mice immunized with the PIV5-L1R and -B5R vectors had VACV titers in lung tissues that were ~1 log lower than that seen in PBS treated control mice on days 4 and 8. By day 12 after challenge, there was no detectable VACV in lungs of mice immunized with PIV5 vectors (* samples at D12, Fig. 4). Given the kinetics of weight loss after VACV challenge of PIV5-immunized mice which begins by day 4, reaches a low point by day 8, and approaches normal levels by day 12, these results suggest that recovery from disease symptoms and protection from lethality correlate with clearance of VACV from lung tissue.

Protection from lethal VACV challenge elicited by the PIV5-L1R and -B5R vectors requires B cells but not CD8+ cells

To define the mechanism of protection mediated by the PIV5 vectors, groups of 7 mice were immunized i.N. as described above in a prime-boost protocol with PBS, sublethal VACV or a combination of both PIV5-L1R and PIV5-B5R vectors. Eighteen days after boosting with PIV5 vectors, CD8+ cells were depleted from mice for 4 consecutive days by daily administration of an anti-CD8 monoclonal antibody as detailed in Materials and methods. Flow cytometric analysis showed that anti-CD8 treatment resulted in a decrease of CD8+, CD3+ (CD8+ T cells) to less than 1% of total splenic cells (data not shown). After i.N. challenge with 20 MTD50 of VACV, mice were monitored for lethality and disease..

Fig. 3. Pathology in nasal tissue of vaccinated mice after lethal i.N. VACV challenge. Mice were vaccinated i.N. with PBS, a sublethal dose of VACV, or prime and boost with 10^6 PFU of both PIV5-L1R and PIV5-B5R as described in the legend to Fig. 2. Twenty one days after the boost, mice were challenged i.N. with 20 MTD50 of VACV. Seven d after challenge, tissues were evaluated histologically. Pictures represent H&E staining of a cross section of nasal cavities and olfactory lobes of the brain. Boxes in 2× pictures outline the area shown in higher magnification in the 10× panels. Panels C and D from the PBS-treated control mice show necrosis of the nasal epithelium with intense inflammation which extends into the brain through the cribiform plate. White arrows (2×) indicate the disruption of integrity of cribiform plate into the adjacent olfactory lobes and adjacent inflammation. The black arrows (10×) show areas of nasal epithelial ulceration. Panels E and F from mice immunized with the PIV5-L1R and PIV5-B5R show minimal fibrinous inflammatory exudate in the nasal cavity and minimal tissue disruption. Panels A and B from the sublethal VACV control animal are within normal limits.
symptoms. As shown in Fig. 5A, PBS-treated control mice succumbed to lethal infection by days 8–10 (closed triangles), whereas all of the CD8-depleted mice that had been immunized with PIV5-L1R/BS5 vectors were completely protected (open circles). Some CD8-depleted control mice that had received a single sublethal dose of VACV also succumbed to VACV challenge (closed squares), a finding that is consistent with previous reports for a role of cellular immunity in the case of some VACV infections (Belyakov et al., 2005; Wyatt et al., 2004). Although PIV5-immunized mice were protected from lethality they still showed disease symptoms such as hunching and loss of weight (data not shown). For PIV5-immunized mice, the magnitude of weight loss (~20–25%) and kinetics of weight loss (maximal at day 8 post challenge) were very similar to that seen without CD8 depletion (data not shown). Thus, protection from VACV lethality induced by PIV5-L1R/BS5 does not depend on CD8+ cells.

To determine the role of B cells in protection elicited by the PIV5-based vectors, Jh mice which lack B cells were immunized IN. in a prime-boost protocol as described above and then challenged IN. 21 days after the boost with 20 MTD50 of VACV. Lethality and disease symptoms were monitored daily. As shown in Fig. 5B, Jh mice immunized with the PIV5-L1R/BS5 vectors succumbed to VACV challenge at a rate that was only slightly delayed compared to that seen with the PBS-treated control mice. By contrast, control mice that were immunized with a sublethal dose of VACV were fully protected. Jh mice that had been immunized with PBS or with the PIV5 vectors showed the appearance of disease symptoms such as loss of weight and hunching between day 4 and day 8 post VACV challenge (data not shown). Taken together, these data indicate that protection from VACV challenge that is elicited by the PIV5-L1R and PIV5-BS5 vectors requires B cells but not CD8+ cells.

Antibody responses to infection with PIV5-L1R and PIV5-BS5 vectors

To assay anti-L1R and anti-BS5 antibody responses, mice were immunized IN. with 10⁶ PFU of either PIV5-L1R or PIV5-BS5 and serum was collected at day 14 and day 21. Mice were then boosted with an equivalent amount of virus and serum was collected at day 4 post boost. On day 10 post boost, mice were sacrificed and bronchoalveolar lavage (BAL) fluid was collected. Levels of serum IgG specific for L1R, B5R and PIV5 were determined using previously described ELISAs based on reactivity against purified L1R, B5R or PIV5 particles (Braxton et al., 2010; Capraro et al., 2008; Delaney et al., 2010). Likewise, BAL fluid was tested in ELISA for antigen-specific IgA and IgG responses.

As shown in Fig. 6A, the PIV5-L1R and PIV5-BS5 vectors elicited very low serum IgG levels on day 14 that were specific for L1R (open triangles) and BS5 (closed squares). By 21 day post primary immunization, titers were slightly increased with a few animals failing to show seroconversion (Fig. 6A). By day 4 post boost however, nearly all animals had seroconverted. This result contrasts with anti-L1R and anti-BS5 responses elicited by sublethal VACV infection which has been shown previously in this same ELISA system to produce titers of 10⁴ and 10², respectively (Braxton et al., 2010). Similarly, the PIV5 vectors elicited anti-L1R and anti-BS5 IgA and IgG titers in BAL that were at or below the limit of detection in this ELISA (Fig. 6B). This low BAL Ig titer against L1R and B5R contrasted with very strong anti-PIV5 IgA and IgG titers in BAL (Fig. 6C) which averaged 10³ and 10⁴, respectively. These results are similar to those published previously showing that VSV vectors expressing L1R and B5R elicit low titers against these two VACV proteins (Braxton et al., 2010).

VACV can exist in two major infectious forms: the extracellular enveloped virion (EEV) and the intracellular mature virion (IMV) which
may differ in requirements for neutralization. (Fogg et al., 2004; Hooper et al., 2000). To determine if the PIV5 vectors elicited antibodies capable of neutralizing IMV form of VACV, sera from animals immunized with a combination of PIV5-L1R and -B5R were analyzed in an in vitro neutralization assay in which 100 PFU of the IMV VACV was incubated with dilutions of serum before determining remaining infectivity by plaque assay. As shown in Fig. 6D, sera from animals immunized with PIV5-L1R and -B5R vectors contained a statistically significant level of neutralizing activity (estimated at 1:20 dilution to reduce infectivity by 50%). It is noteworthy that assaying these dilutions of serum in vitro may give a biased view relative to the undiluted nature of blood. By contrast, sera from control mice immunized with PBS showed no significant reduction in plaques (Fig. 6E). These data indicate that while the ELISA shows low antibody titers against L1R and B5R in PIV5-immunized animals, these sera are capable of neutralizing VACV in a functional assay.

To determine if PIV5-based vectors elicited antibodies that were also capable of neutralizing EEV VACV, sera from animals immunized with a combination of PIV5-L1R and -B5R were analyzed in a plaque reduction assay with the EEV form of VACV. As shown in Fig. 7, sera from control mice immunized with PBS or with a control vector which lacked a foreign gene (PIV5) showed no neutralization of EEV VACV, whereas sera from control VACV immunized mice was effective in neutralization. Importantly, sera from mice immunized with PIV5-L1R and -B5R was capable of neutralizing the EEV form of VACV to a slightly lower extent compared to neutralization of the IMV form shown in Fig. 6. Thus, immunization with PIV5 vectors expressing B5R and L1R elicits neutralizing antibodies capable of inactivating both the IMV and EEV forms of VACV.

**PIV5-based vectors provide long term protection from VACV challenge**

The protection from VACV elicited in mice by PIV5-L1R and PIV5-B5R vectors was long lasting. This is demonstrated in Fig. 8 where mice were given a prime-boost immunization I.N. with PBS as a control, a
combination of \(10^6\) PFU of PIV5-L1R and PIV5-B5R or a single sublethal dose of VACV. Mice were then housed for 1.5 years before challenging I.N. with 20 MTD50 of VACV. As shown in Fig. 8A, mice that had been immunized with sublethal doses of VACV or with the PIV5 vectors were protected from lethal challenge. One of these aged PIV5-immunized mice died during this experiment due to necrosis resulting from tail bleeding (star Fig. 8A), but this was not due to lack of protection from I.N. challenge. As with newly immunized and challenged animals, these mice that had been previously immunized with PIV5-L1R and PIV5-B5R and challenged at later points showed a loss of weight 8 day post challenge, but then rapidly regained weight to nearly 90% of initial values (Fig. 8B).

Serum from mice that had been immunized with the PIV5 vectors contained statistically significant levels of neutralizing antibodies out to 1.5 years after immunization. This is evident in Fig. 8C where a 1:25 dilution of serum from mice immunized with the PIV5-L1R and -B5R vectors reduced IMV VACV infectivity by ~70% compared to the ~90% seen with control sera from control mice that had received sublethal VACV infection (Fig. 8D). Taken together, the above data indicate the PIV5 vectors elicit protection from lethal I.N. VACV challenge that: 1) requires a prime-boost combination by the I.N. route, 2) is seen with either PIV5-L1R or PIV5-B5R, but is most effective when the L1R-expressing vector is included, 3) reduces VACV induced pathology in the nasal tissue, 4) requires B cells but is not affected by depletion of CD8+ cells and 5) is long lasting in mice out to at least 1.5 years after immunization.

Discussion

The goal of the work described here was to test the ability of PIV5-based vectors to elicit protective immunity against lethal I.N. VACV challenge. The I.N. infection route was chosen here based on the need for new vaccines to protect against aerosolized VACV which may have different requirements for protection from challenge by other routes (Kaufman et al., 2008) and the assumption that parainfluenza viruses would elicit the most robust responses by infection through the respiratory route. Our results indicate that PIV5 vectors expressing the VACV L1R and B5R proteins confer long lasting protective immunity against lethal I.N. VACV challenge. Protection from VACV-mediated lethality required a prime plus boost immunization protocol administered by the I.N. route, depended on B cells but not CD8+ cells and was capable of protecting mice for longer than 1.5 years after immunization. While immunization with vectors expressing B5R alone conferred at least some protection, the most effective immunization involved PIV5 expressing L1R alone or in combination with B5R. Taken together these results support the further development of PIV5-based vectors for immunization against highly pathogenic and complex human viruses such as poxviruses.

Mice responded to our PIV5 vectors by generating high ELISA titers of antibodies to the PIV5 vector and but relatively low ELISA titers of antibodies to VACV L1R and B5R proteins. We have previously shown that WT PIV5 elicits a very strong anti-PIV5 antibody response detected in serum (Capraro et al., 2008) and here we extend this analysis to
include very high anti-PIV5 IgG and IgA responses in BAL (Fig. 6). By contrast, results from ELISA data showed that the serum antibody responses to L1R and BSR were at low levels and were not detectable in BAL (Fig. 6). This is consistent with previous work showing that the L1R and BSR proteins are poorly immunogenic when expressed outside of the context of the native VACV. This is also reflected in the need for multiple vaccinations with pure L1R and BSR proteins to generate high antibody titers that provide protection (Berhanu et al., 2008; Braxton et al., 2010; Delaney et al., 2010; Fogg et al., 2004; Hooper et al., 2000; Xiao et al., 2007). It is known that there is an initial innate response in mouse lung to PIV5 infection. However, as we have shown that PIV5 is cleared from the respiratory tract by 9 days after infection (Capraro et al., 2008), it is unlikely that an innate response to the vector contributes substantially to protection from lethal VACV infection. This is further supported by the key findings that protection requires B cells and that mice are protected up to 1½ years after immunization with the PIV5 vectors. Importantly however, the PIV5 vectors elicited protection in mice that was dependent on B cells and generated functional anti-VACV antibody titers were easily detected during in vitro neutralization assays (Figs. 5 and 6). These data suggest that PIV5 vectors elicit memory B cells that respond to secondary exposure during VACV challenge by increasing levels of neutralizing anti-VACV antibodies. Alternatively, protection from VACV challenge could involve antibody-mediated cellular cytotoxicity (ADCC) or complement-mediated cell lysis, both of which are dependent on antibodies to VACV proteins. The role of complement in VACV protection has been shown previously (Benhnia et al., 2009), and is currently being tested in the context of PIV5-based vectors.

In contrast to recent work with VSV-based vectors expressing L1R and BSR where a single immunization provided protection (Braxton et al., 2010), our PIV5 vector-mediated protection from lethal L.N. VACV infection required a prime and a boost immunization administered by the L.N. route. This may reflect a higher level or prolonged expression of antigens in the airways of mice infected with VSV vectors compared to PIV5 vectors. In view of the finding that the anti-PIV5 antibody response to primary L.N. infection of mice is very strong (titers of ~10^6, Capraro et al., 2008), it is somewhat surprising that a boost with the same PIV5 vectors promoted protection from VACV challenge. This is particularly true of anti-PIV5 titers in the BAL, which were very high for IgA. Work is in progress to define the mechanism by which boosting with the PIV5 vectors influences protection from VACV challenge even in the face of a strong response due to prior exposure to PIV5.

While the PIV5 vectors clearly protected mice from succumbing to a lethal VACV infection, immunized animals displayed some signs of illness following VACV challenge. This was most notable in PIV5-immunized mice by the loss of weight starting at days 3–4, but this was also evident by signs of illness such as hunching, ruffled fur, conjunctivitis, labored breathing, lethargy and unresponsiveness to stimulus (not shown). Importantly, the kinetics of appearance of illness in PIV5-immunized mice was delayed and less severe compared to control PBS-treated animals, and the PIV5-immunized animals showed an improvement to near normal properties by day 12 post challenge. Similar results have been shown for animals vaccinated with purified VACV proteins (Delaney et al., 2010; Fogg et al., 2004) and with VSV-based vectors expressing L1R and BSR (Braxton et al., 2010), where immunized animals lost weight following VACV challenge even though they were protected from lethality. The disease symptoms in PIV5-immunized animals could reflect a delay in response of memory B cells in PIV5 immunized animals to VACV antigens during the challenge. Additional possibilities include a lower immune response to PIV5-based vaccination due to the fact that PIV5 immunized animals are exposed to only two of the multiple antigenic proteins that expressed during a VACV infection (Berhanu et al., 2008; Fogg et al., 2004; Hooper et al., 2000), or to alternative conformations of BSR and L1R when expressed from PIV5 versus bone fide VACV infection. In the latter case, we engineered expression of soluble versions of L1R and BSR to enhance release from infected cells and possible uptake of secreted antigen. However, as the immunogenicity of L1R is particularly sensitive to conformational changes (Su et al., 2007), PIV5-expressed L1R may not elicit strong antibody responses due to its expression as an HA-tagged cytoplasmic protein.

There is intense interest in developing paramyxovirus-based vectors for vaccination and therapeutic applications (Bukreyev et al., 2006; Lamb and Parks, 2007; von Messling and Cattaneo, 2004), and PIV5-based vectors have attractive properties relative to other vectors based on viruses that are associated with human diseases. These desirable PIV5 properties including infections are largely noncytopathic in most cell types, and that PIV5 is not associated with any disease in humans (Goswami et al., 1984). In ferrets and mice, PIV5 stimulates strong antibody and T cell responses, is cleared from respiratory tissues by 7–9 days pi without evidence of systemic infection (Capraro et al., 2008) and induces no overt pathology. As discussed previously (Capraro et al., 2008), the ferret model may be a more appropriate system for analysis of features of the PIV5 vectors, since the mouse is not a good predictor of viral permissiveness/tropism in humans. PIV5 can elicit strong systemic mucosal IgG and IgA responses, even when delivered by different routes. PIV5 is known to very high titers (>10^10 PFU/ml) in Vero cells, an approved cell line for vaccine work. Finally, anti-PIV5 sero-prevalence can be relatively low in many human populations (Hsiung, 1972; Johnson et al., 2008). A PIV5 vector was shown to elicit protective immunity in mice against influenza virus (Tompkins et al., 2007), although the mechanism of protection in that study was not addressed.

There have been previous reports of PIVS association with human diseases, including Multiple Sclerosis (Goswami et al., 1984). At the time, these were attractive associations, largely due to PIV5’s property of readily establishing persistent infections of cells with low levels of pathology (Choppin, 1964). Importantly, all of these claims have been disproven (McLean and Thompson, 1989) and it is currently thought that PIVS is not associated with any human disease. PIV5 variants have been isolated from samples from human patients (Chatziandreou et al., 2004). The divergence of sequence between these PIV5 isolates indicates that these are not a common lab contaminant, but represent bone fide human infections. PIV5 does not establish persistent infections in mice or ferrets and viral load appears to be restricted to the respiratory tract (Capraro et al., 2008). Whether PIV5 establishes persistent infections in humans is not known.

Our work raises the important question of how virus-based vectors could be improved upon in order to generate a more complete protective immunity in different compartments of the respiratory tract and reduce disease symptoms. We have previously shown that engineered expression of the TLR5 agonist flagellin enhanced the ability of PIV5 to stimulate human dendritic cells and T cells (Arimilli et al., 2008). Likewise, we have shown that PIV5 vectors based on RNA synthesis mutants are potent activators of innate and adaptive immunity (Capraro et al., 2008; Manuse and Parks, 2009). These results with PIV5 variants support the general hypothesis that paramyxovirus vectors can be designed to express a target antigen along with immuno-modulatory factors that elicit a broader response to protect against both lethality as well as reduce disease symptoms.

Materials and methods

Cells and viruses

The genes for VACV L1R and BSR have been described previously (Al dez-Carroll et al., 2005a, 2005b). The L1R and BSR open reading frames were modified by PCR to encode a C-terminal HA tag, and then inserted into the PIV5 cDNA encoding the intergenic region at the HN–L junction. As described previously (He et al., 1997; Parks et al., 2002), the new genes were flank ed by PIV5 transcription signals derived from the NP–P gene junction and were fully functional in directing transcription.
of the foreign gene as an additional transcription unit. Further details of the cloning steps are available on request. Reombinant viruses individually expressing L1R and B5R were recovered as described previously (Parks et al., 2002) from cDNA plasmids kindly provided by Robert Lamb (Northwestern University) and Biao He (University of Georgia). The TK-expressing PIV5 has been described (Parks et al., 2002). For in vivo experiments, viruses were concentrated by centrifugation through a glycerol cushion (5 h; 25,000 RPM; SW28 rotor), and virus pellets were resuspended in a small volume of DMEM containing 0.75% BSA.

The IMV form of the Western Reserve (WR) strain of VACV was prepared and purified as described by Delaney et al. (2010). The EEV form of VACV was prepared exactly as described by Benhnia et al. (2009) and was stored at 4 °C prior to use in assays. Neutralization assays were carried out as described previously (Johnson et al., 2008). Briefly, 100 PFU of VACV were treated at 37 °C with varying concentrations of immune or control serum for 1 h. All sera were heat inactivated as described previously (Johnson et al., 2008). After incubation, viral titers were determined by plaque assays on CV-1 cells. Results were the average of six reactions, with the significance of data points calculated using the student’s t-test.

**Immunization of mice and VACV challenge**

All research performed on mice in this study complied with federal and institutional guidelines set forth by Wake Forest University Animal Care and Use Committee. Female BALB/c mice (5–8 weeks of age) were purchased from Charles River. Jb B cell-deficient mice were of BALB/c origin. Mice were anesthetized with avertin and immunized intranasally (i.n.) as previously described (Capraro et al., 2008; Gray et al., 2003) with 10⁶ PFU of purified PIV5 vector in 20 µl of PBS. Control animals were given a sublethal dose of 0.1 Median Tolerated Dose (MTD₀) of VACV (100 PFU) by i.n. administration in 10 µl of PBS. This dose of VACV does not allow mice to succumb by 6 days postinoculation (dpi). At the indicated days pi, mice were euthanized as required by IACUC guidelines of Wake Forest University Health Sciences. At the indicated days pi, mice were bleed from the tail vein, and blood was allowed to clot overnight at 4 °C before clarification by centrifugation. ELISAs were carried out as described previously for PIV5-specific antibodies (Capraro et al., 2008) for L1R and B5R (Braxton et al., 2010; Delaney et al., 2010). Proteins used in the ELISA were baculovirus-derived recombinant histidine-tagged B5R and L1R proteins generated in cultures of Sf9 cells and purified by metal affinity resin as described previously (Delaney et al., 2010).

For Western blotting, 6-well dishes of cells were infected as described in the figure legends. At each time point, media was collected, concentrated by TCA precipitation, and resuspended in 1% SDS. Cells were washed with PBS and lysed in 1% SDS. Protein concentration was determined by BCA assay (Pierce Chemicals). For each timepoint, the entire media sample and 2 µg of cell lysate was analyzed by gel electrophoresis under reducing conditions. Typically recovery of cell lysate was ~500–700 µg of protein. Thus, 2 µg of protein was resolved on a 10%–4% gradient polyacrylamide gel. The proteins were visualized by horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (Pierce Chemicals).

**Pathology**

The heads of the mice were removed and preserved whole in 10% neutral buffered formalin for at least 24 h, and then decalcified in Decalcifier-2 (Polysciences) for 6–8 h before cross sections were made through the noses at the level of the olfactory lobes of the brains. The tissues were returned to formalin, embedded in paraffin, processed routinely for histology, cut at 6 µm, and stained with hematoxylin and eosin (H and E). The sections were examined by a board certified veterinary pathologist and are representative of two experiments.

**Acknowledgments**

We are grateful to Drs. Biao He and Robert A. Lamb for the original gift of the PIV5 infectious clones, Ellen Young and Lara Voltz-Smith for technical support. We are grateful for the excellent technical help that James Phipps provided in generating the soluble L1 and B5 proteins. This work was supported by NIH grant AI-060642 (SBM) and AI-081022 (GDP).

**References**

Ahlers, J.D., Franchini, G., Moss, B., Berzofsky, J.A., 2005. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U.S.A. 100, 9458–9463.

Benhnia, M.R., McCausland, M.M., Moyron, J., Laudenslager, J., Granger, S., Rickert, S., Koirazova, L., Kubo, R., Kató, S., Crotty, S., 2009. Vaccinia virus extracellular neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein BSR. J. Virol. 79, 6260–6271.

Aldar-Carroll, L., Whitbeck, J.C., Ponce de Leon, M., Lou, H., Hirao, L., Isaacs, S.N., Moss, B., Eisenberg, R.J., Cohen, G.H., 2005a. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein BSR. J. Virol. 79, 6260–6271.

Aldar-Carroll, L., Whitbeck, J.C., Ponce de Leon, M., Lou, H., Pannell, L.K., Lebowitz, J., Fogg, C., White, C.L., Moss, B., Eisenberg, R.J., Cohen, G.H., 2005b. Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology 341, 59–71.

Arimilli, S., Johnson, J.B., Clark, K.M., Graff, A.H., Alexander-Miller, M.A., Mizel, S.B., Parks, G.D., 2008. Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function. J. Virol. 82, 10975–10985.

Bell, E., Shamim, M., Whitbeck, J.C., Sfyrora, G., Lambiris, J.D., Isaacs, S.N., 2004. Antibodies against the EEV BSR protein are mainly responsible for EEV neutralization capacity of vaccinia virus immune globulin. Virology 325, 425–431.Belyakov, I.M., Earl, P., Dzutsev, A., Kuznetsov, V.A., Lemon, M., Wyatt, L.S., Snyder, J.T., Eisenberg, R.J., Cohen, G.H., 2005a. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein BSR. J. Virol. 79, 6260–6271.

Bell, E., Shamim, M., Whitbeck, J.C., Sfyrora, G., Lambiris, J.D., Isaacs, S.N., 2004. Antibodies against the EEV BSR protein are mainly responsible for EEV neutralization capacity of vaccinia virus immune globulin. Virology 325, 425–431.

Benhnia, M.R., McCausland, M.M., Moyron, J., Laudenslager, J., Granger, S., Rickert, S., Koirazova, L., Kubo, R., KatO, S., Crotty, S., 2009. Vaccinia virus extracellular
enveloped virion neutralization in vitro and protection in vivo depend on complement. J. Virol. 83, 1201–1215.
Berhanu, A., Wilson, R.L., Kirkwood-Watts, D.L., King, D.S., Warren, T.K., Lund, S.A., Brown, L.T., Krupkin, A.K., Vandermeers, V., Weimers, W., Honeychurch, K.M., Grosenbach, D.W., Jones, K.F., Hruby, D.E., 2008. Vaccination of BALB/c mice with E. coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J. Virol. 82, 3517–3529.
Braxton, C.L., Puckett, S.H., Mizeb, S.B., Lyles, D.S., 2010. Protection against lethal vaccinia virus challenge using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J. Virol. 84, 3552–3561.
Bukreyev, A., Skiadopoulos, M.H., Murphy, B.R., Collins, P.L., 2006. Nonsegmented negative-sense viruses as vaccine vectors. J. Virol. 80, 10293–10306.
Buller, R.M., Palumbo, G.J., 1991. Poxvirus pathogenesis. Microbiol. Rev. 55, 80–122.
Caprao, G.A., Johnson, J.J., Kock, N.D., Parks, G.D., 2008. Growth and antibody responses to respiratory tract infection of ferrets and mice with WT and P/V mutants of the paramyxovirus Simian Virus 5. J Virol. 84, 416–426.
Chatziantoniou, N., Stock, N., Young, D., Andrejeva, J., Hgmaier, K., McGeoch, D.J., Randall, R.E., 2004. Relationships and host range of human, canine, simian and porcine isolate of SV5. J. Gen. Virol. 85, 3007–3016.
Choppin, P.W., 1964. Multiplication of a myxovirus (SV5) with minimal cytopathic effects and without interference. Virology 23, 224–233.
Delaney, K.N., Phipps, J.F., Johnson, J.J., Mizeb, S.B., 2010. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol. 23, 201–210.
Engelstad, M., Howard, S.T., Smith, G.L., 1992. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188, 801–810.
Fogg, C., Lustig, S., Whitbeck, J.C., Eisenberg, R.J., Cohen, G.H., Moss, B., 2004. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78, 10230–10237.
Franke, C.A., Wilson, E.M., Hruby, D,E., 2008. Vaccination of BALB/c mice with E. coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal respiratory tract infection of ferrets and mice with WT and P/V mutants of the paramyxovirus Simian Virus 5. J Virol. 84, 416–426.
Galmiche, M.C., Goenaga, J., Wittek, R., Rindesbacher, L., 1999. Neutralizing and enveloped virion neutralization in vitro and protection in vivo depend on complement. J. Virol. 83, 1201–1215.
He, B., Paterson, R.G., Ward, C.D., Lamb, R.A., 1997. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 237, 249–256.
Hooper, J.W., Custer, D.M., Smaljohn, C.S., Smaljohn, A.L., 2000. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against lethal poxvirus challenge. Virology 266, 329–339.
Hooper, J.W., Custer, D.M., Thompson, E., 2003. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306, 181–195.
Hsiung, G.D., 1972. Parainfluenza-5 virus. Infection of man and animals. Prog. Med. Virol. 14, 241–274.
Jacobs, B.L., Langland, J.O., Kühker, K.V., Denzler, K.L., White, S.D., Holeczek, S.A., Wong, S., Huynt, T., Baskin, C.R., 2005. Vaccinia virus vaccines: past, present and future. Antiviral Res. 64, 1–13.
Johnson, J.B., Caprao, G.A., Parks, G.D., 2008. Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses PIV5 and Mumps virus. Virology 376, 112–123.
Kaufman, D.R., Goudsmit, J., Holterman, L., Ewald, B.A., Denholtz, M., Devoy, C., Giri, A., Grandpre, L.E., Heraud, J.M., Franchini, G., Seaman, M.S., Havenga, M.J., Barouch, D.H., 2008. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J. Virol. 82, 6829–6837.
Lamb, R.A., Parks, G.D., 2007. Paramyxoviridae: the viruses and their replication, In: Fields, B., Knipe, D., Howley, P. (Eds.), Fields’ Virology, 5th ed. Lippincott Williams & Wilkins Publishers, Philadelphia, pp. 1449–1496.
Lustig, S., Fogg, C., Whitbeck, J.C., Eisenberg, R.J., Cohen, G.H., Moss, B., 2005. Combinations of polyclonal antibodies to proteins of the outer membranes of the two infections forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 79, 13454–13462.
Manuse, M.J., Parks, G.D., 2009. Role for the paramyxovirus genomic promoter in limiting host cell antiviral responses and cell killing. J. Virol. 83, 9057–9067.
McLean, B.N., Thompson, E.J., 1989. Antibodies against the paramyxovirus SV5 are not specific for cerebrospinal fluid from multiple sclerosis patients. J. Neurol. Sci. 92, 261–266.
Moss, B., 2006. Poxvirus entry and membrane fusion. Virology 344, 48–54.
Murphy, B.R., 1994. Mucosal immunity to viruses. In: Ogra, P.L., Lamm, M.E., McGhee, J.K., Mestecky, J., Stobo, J., Benenson, J. (Eds.), Handbook of Mucosal Immunology. Academic Press, San Diego, CA, pp. 333–343.
Parks, G.D., Alexander-Miller, M.A., 2002. High avidity CTL to a foreign antigen are efficiently activated following immunization with a recombinant PIV5. J. Gen. Virol. 83, 1167–1172.
Parks, G.D., Young, V.A., Komnenis, C., Wansley, E.K., Linger, J.L., Cooke, K.M., 2002. Controlled cell killing by a recombinant nonsegmented negative strand RNA virus. Virology 293, 192–203.
Shinoda, K., Wyatt, S.K., Moss, B., 2009. Engineering the vaccinia virus L1 protein for increased antibody response after DNA immunization. Virol. J. 6, 28.
Su, H.P., Golden, J.W., Gittis, A.G., Hooper, J.W., Gabrischi, D.N., 2007. Structural basis for the binding of neutralizing antibody 7D11 to the poxvirus L1 protein. Virology 368, 331–341.
Tompkins, S.M., Lin, Y., Leser, G.P., Kramer, K.A., Haas, D.L., Howerth, E.W., Xu, J., Bennett, M.J., Durbin, R.K., Durbin, J.E., Tripp, R., Lamb, R.A., He, B., 2007. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology 362, 139–150.
Virgin, S., 2007. Pathogenesis of viral infection: the viruses and their replication, In: Fields, B., Knipe, D., Howley, P. (Eds.), Fields’ Virology, 5th ed. Lippincott Williams & Wilkins Publishers, Philadelphia, pp. 328–388.
von Messling, V., Cattaneo, R., 2004. Toward vaccines and therapies based on negative strand RNA viruses.Curr. Top. Microbiol. Immunol. 283, 281–312.
Wolffe, E.J., Vijaya, S., Moss, B., 1995. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211, 53–63.
Woodland, D.L., Randall, R.D., 2004. Anatomical features of anti-viral immunity in the respiratory tract. Semin. Immunol. 16, 163–170.
Wyatt, L.S., Earl, P.L., Eller, L.A., Moss, B., 2004. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. U.S.A. 101, 4590–4595.
Xiao, Y., Alazad-Carroll, L., Ortiz, A.M., Whitbeck, J.C., Alexander, E., Lou, H., Davis, H.L., Braciale, T.J., Eisenberg, R.J., Cohen, G.H., Isaacs, S.N., 2007. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25, 1214–1224.